Skip to content
DD STOCK
  • Home
  • technology
  • Unnecessary
  • Health Care
  • Necessary
  • Financials
  • Energy
  • Industrials
  • Basic Materials
  • Telecommunications
  • Utilities
DD STOCK
  • Home
  • technology
  • Unnecessary
  • Health Care
  • Necessary
  • Financials
  • Energy
  • Industrials
  • Basic Materials
  • Telecommunications
  • Utilities

Home » Regeneron Pharmaceuticals » Truist Securities maintains Regeneron Pharmaceuticals (NASDAQ:REGN) $1045 price target

Truist Securities maintains Regeneron Pharmaceuticals (NASDAQ:REGN) $1045 price target

By legume / August 17, 2023 / Regeneron Pharmaceuticals, Truist Financial

Truist Securities analyst Robyn Karnauskas reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and maintains $1045 price target.

Previous

Goldman Sachs Cuts Target (NYSE:TGT) Price Target to $168 From $185

Next

Citigroup lowers Walt Disney (NYSE:DIS) price target from $125 to $120

Recent Posts

  • Snowflake (SNOW) Q1 2026 Earnings Call Transcript
  • Walmart, Inc. (WMT) Q1 2026 Earnings Call transcript
  • Applied Materials (AMAT) Q2 2025 Earnings Call Transcript
  • Cisco Systems, Inc. (CSCO) Q3 2025 Earnings Call Transcript
  • Can UnitedHealth’s New Boss Succeed Where Other ‘Boomerang’ CEOs Failed?

Recent Comments

No comments to show.

Tag Cloud

Adobe Alphabet Amazon AMD Apple Bank of America Barclays Boeing Broadcom Citigroup Costco CrowdStrike Deutsche Bank Disney Eli Lilly Estee Lauder FedEx Goldman Sachs Intel Jefferies JPMorgan Lululemon McDonald Meta Platforms Micron Technology Microsoft Mizuho Morgan Stanley Netflix Nike Nvidia Oppenheimer Piper Sandler Raymond James Royal Bank of Canada Salesforce Snowflake Starbucks Target Tesla Uber UBS Walmart Wedbush Wells Fargo

友情链接:豆豆小说 股票研究报告 股票行情分析

Copyright © 2025 DD STOCK

Scroll to Top